Trial Profile

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mercaptamine bitartrate (Primary)
Indications Huntington's disease
Focus Registrational; Therapeutic Use
Acronyms CYST-HD

Most Recent Events

10 Dec 2015 Results of 36-month efficacy published in a Raptor Pharmaceuticals media release.
06 Aug 2015 According to a Raptor media release, 36-month data from this study is expected to be reported in the fourth quarter of 2015.
07 May 2015 According to a Raptor media release, 36-month data from this study is expected in second-half of 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com